Edition:
United Kingdom

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

8.03USD
15 Dec 2017
Change (% chg)

$-0.97 (-10.78%)
Prev Close
$9.00
Open
$8.90
Day's High
$8.98
Day's Low
$8.00
Volume
495,305
Avg. Vol
50,214
52-wk High
$15.65
52-wk Low
$6.38

Latest Key Developments (Source: Significant Developments)

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

Syndax Pharmaceuticals Q2 loss per share $0.47
Tuesday, 9 Aug 2016 

Syndax Pharmaceuticals Inc : Syndax Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.47 .Progressing to phase 2 of ENCORE 601 in NSCLC and Melanoma.  Full Article

Syndax expands pipeline with license agreement for UCB6352
Wednesday, 6 Jul 2016 

Syndax Pharmaceuticals : Syndax expands pipeline with exclusive worldwide license agreement for UCB's colony stimulating factor 1 receptor (CSF-1R) antibody program .License deal for UCB6352, clinical trials to begin in 2016; cash, marketable securities sufficient to fund payment obligations.  Full Article

Syndax Pharmaceuticals posts Q1 loss per share of $2.85
Monday, 16 May 2016 

Syndax Pharmaceuticals Inc : Syndax Pharmaceuticals reports first quarter 2016 financial results and provides business update following IPO . Q1 loss per share $2.85 .Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

Merck KGaA,Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer
Monday, 4 Jan 2016 

Merck KGaA:Says Co, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals entered into a collaboration to evaluate combination of avelumab and entinostat in ovarian cancer.Says financial terms of the agreement were not disclosed.This is an exclusive agreement between the alliance and syndax to study the combination of two investigational agents in ovarian cancer.Says syndax will be responsible for conducting the phase ib/ii clinical trial in ovarian cancer.  Full Article

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update